Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-gene mutation metastatic castrate-resistant prostate cancer.

BMJ case reports - 23 Jul 2021

Christy Joshua, Kandah Emad, Kesari Kavitha, Singh Trevor

Abstract excerpt

Gene panel sequencing of metastatic castrate-resistant prostate cancer (mCRPC) can assist in identifying appropriate targeted therapies. Although some studies have reported single DNA mutations, this is the first case of mCRPC with five different DNA mutations based on gene panel analysis. The patient, a 75-year-old man, initially presented with haematuria. Laboratory investigation revealed elevated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 34301684
DOI: 10.1136/bcr-2021-243124
PMCID: PMC8311301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-gene mutation metastatic castrate-resistant prostate cancer.PMID 34301684Read ↗

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read ↗

Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.Semantic proximity Read ↗

The Current Status of Comprehensive Genomic Profiling in the Management of Metastatic Castration-Resistant Prostate Cancer: A Study from a Cooperative Hospital for Cancer Genomic Medicine in Japan.Semantic proximity Read ↗

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical OutcomeSemantic proximity Read ↗

The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.Semantic proximity Read ↗

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.Semantic proximity Read ↗

Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer.Semantic proximity Read ↗

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Semantic proximity Read ↗

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation.Semantic proximity Read ↗

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.